Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

NCT02635061 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: ACY-241
DRUG: Nivolumab

Sponsor

Celgene